Early research (Phase 1)UnknownNCT01454479
What this trial is testing
A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma
Who this might be right for
Recurrent Endometrial Cancer
Hung-Hsueh Chou 24